PRC
IOVA icon

Pearl River Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Pearl River Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,148
Closed -$232K – 474
2021
Q4 		$232K Buy
+12,148
New +$267K 0.06% 348
2021
Q2 		– Sell
-18,249
Closed -$578K – 492
2021
Q1 		$578K Buy
18,249
+10,565
+137% +$438K 0.18% 171
2020
Q4 		$357K Sell
7,684
-2,402
-24% -$95.4K 0.13% 247
2020
Q3 		$332K Sell
10,086
-11,364
-53% -$348K 0.14% 230
2020
Q2 		$589K Buy
+21,450
New +$705K 0.29% 110
2019
Q1 		– Sell
-700
Closed -$6K – 553
2018
Q4 		$6K Buy
+700
New +$6.75K 0.03% 681

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Pearl River Capital's IOVA Position: Q1 2022 in Review

Pearl River Capital sold out of Iovance Biotherapeutics (IOVA) in Q1 2022, closing a stake of 12,148 shares — an estimated $232K sold.

Pearl River Capital first reported a position in IOVA in Q4 2018 and held it in 6 quarters. The position peaked at $589K in Q2 2020. 250 funds tracked by Wall St. Rank hold IOVA as of Q1 2022.

  • Pearl River Capital reported no remaining Iovance Biotherapeutics position as of Q1 2022 after selling out during the quarter.
  • Pearl River Capital sold 12,148 Iovance Biotherapeutics shares in Q1 2022, an estimated $232K.
  • Pearl River Capital first reported a position in Iovance Biotherapeutics in Q4 2018 and held it in 6 quarters.
  • Pearl River Capital's Iovance Biotherapeutics position peaked at $589K in Q2 2020.
  • 250 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2022.

Based on Pearl River Capital's 13F filing for Q1 2022, filed 13 May 2022.